LMO4通过诱导RAB17降解和铁灭性耐药性来促进OSCC的进展
JiaJia Fan1, Hongyan Zhang2, Lin Liu3
1Department of Oral Maxillofacial-Head and Neck Surgery, School of Stomatology, China Medical University, Oral Diseases Laboratory of Liaoning, 117 Nanjing North Road, Heping District, Shenyang, Liaoning, 110000, China.
Cell death & disease
|November 10, 2025
概括
仅LIM蛋白4 (LMO4) 在口腔状细胞癌 (OSCC) 中升高,通过降低瘤抑制剂RAB17来驱动癌症进展和铁亡抵抗. 针对这种LMO4-RAB17通路可能为OSCC提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 口腔状细胞癌 (OSCC) 是一种具有不良患者结局的侵袭性恶性瘤.
- 仅LIM蛋白4 (LMO4) 在OSCC病原发生中的作用尚不清楚.
- 在各种上皮癌中,LMO4被认为是转录的共同调节剂.
研究的目的:
- 在OSCC中研究LMO4的表达和功能.
- 阐明LMO4影响OSCC进展的分子机制.
- 评估在OSCC中准LMO4途径的治疗潜力.
主要方法:
- 在OSCC组织中对LMO4表达的定量分析和患者生存数据.
- 在体外细胞培养实验中评估OSCC细胞的增殖,迁移和铁亡.
- 乌比奎丁-蛋白酶体系统分析和RAB17蛋白质水平评估.
- 在体内研究使用裸体老鼠异种移植模型.
主要成果:
- 在OSCC组织中,LMO4表达显著上调,与整体存活率较差相关.
- 过度表达LMO4促进OSCC细胞的增殖,迁移和耐铁灭的抵抗.
- 通过ubiquitin-proteasome通路,LMO4促进了瘤抑制剂RAB17的降解.
- 恢复RAB17表达可以逆转由LMO4.4诱导的恶性表型.
- 异种移植瘤中的高LMO4水平与瘤生长的增加和RAB17水平的降低相关.
结论:
- 通过调节RAB17稳定性和铁亡,LMO4在OSCC进展中发挥着关键作用.
- LMO4-RAB17轴代表了口腔状细胞癌的潜在治疗标.
- 针对LMO4介导的翻译后调节为OSCC治疗提供了一个新的策略.
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Necrosis
6.3K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
6.3K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Rab Proteins
4.9K
Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
4.9K
Receptor Downregulation in MVBs
2.7K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.7K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
